Roche's response to COVID-19
Since the worldwide recognition of the novel coronavirus pandemic risk in January, our singular focus has been - and continues to be - to support the global response to the outbreak of COVID-19.
Separates RNA from other materials in sample prior to downstream testing (LDTs).
Detects SARS-CoV-2 in currently infected patients with high sensitivity.
Detects a patient’s immune response to SARS CoV-2 with high specificity.
Clinical Decision Support
Biomarkers that provide valuable information to aid in the management of COVID-19 patients.